<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23102063</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2012</Year>
        <Month>10</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1557-8607</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunology and allergy clinics of North America</Title>
          <ISOAbbreviation>Immunol Allergy Clin North Am</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sarcoidosis.</ArticleTitle>
        <Pagination>
          <StartPage>487</StartPage>
          <EndPage>511</EndPage>
          <MedlinePgn>487-511</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.iac.2012.08.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0889-8561(12)00105-1</ELocationID>
        <Abstract>
          <AbstractText>Sarcoidosis is a multisystem granulomatous syndrome with a vast range of clinical manifestations. Since the first description of sarcoidosis in 1869, it has simultaneously intrigued and perplexed generations of physicians. Because sarcoidosis can occur variably in any organ and does not always adhere to classic descriptions, both diagnosis of sarcoidosis and attribution of symptoms can be extremely challenging. The management of sarcoidosis requires consideration of the expected course. Medication is considered when there is risk of irreversible vital organ damage, substantial progression, or symptoms that are affecting quality of life. Recently, a range of steroid-sparing therapies have been adopted for sarcoidosis.</AbstractText>
          <CopyrightInformation>Copyright © 2012. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Culver</LastName>
            <ForeName>Daniel A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. culverd@ccf.org</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Immunol Allergy Clin North Am</MedlineTA>
        <NlmUniqueID>8805635</NlmUniqueID>
        <ISSNLinking>0889-8561</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23102063</ArticleId>
        <ArticleId IdType="doi">10.1016/j.iac.2012.08.005</ArticleId>
        <ArticleId IdType="pii">S0889-8561(12)00105-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23102063</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2012</Year>
        <Month>10</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1557-8607</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunology and allergy clinics of North America</Title>
          <ISOAbbreviation>Immunol Allergy Clin North Am</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sarcoidosis.</ArticleTitle>
        <Pagination>
          <StartPage>487</StartPage>
          <EndPage>511</EndPage>
          <MedlinePgn>487-511</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.iac.2012.08.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0889-8561(12)00105-1</ELocationID>
        <Abstract>
          <AbstractText>Sarcoidosis is a multisystem granulomatous syndrome with a vast range of clinical manifestations. Since the first description of sarcoidosis in 1869, it has simultaneously intrigued and perplexed generations of physicians. Because sarcoidosis can occur variably in any organ and does not always adhere to classic descriptions, both diagnosis of sarcoidosis and attribution of symptoms can be extremely challenging. The management of sarcoidosis requires consideration of the expected course. Medication is considered when there is risk of irreversible vital organ damage, substantial progression, or symptoms that are affecting quality of life. Recently, a range of steroid-sparing therapies have been adopted for sarcoidosis.</AbstractText>
          <CopyrightInformation>Copyright © 2012. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Culver</LastName>
            <ForeName>Daniel A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. culverd@ccf.org</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Immunol Allergy Clin North Am</MedlineTA>
        <NlmUniqueID>8805635</NlmUniqueID>
        <ISSNLinking>0889-8561</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23102063</ArticleId>
        <ArticleId IdType="doi">10.1016/j.iac.2012.08.005</ArticleId>
        <ArticleId IdType="pii">S0889-8561(12)00105-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
